Fostamatinib Disodium / R935788
Fostamatinib Disodium / R935788 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 75.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
60.0%
3 of 5 finished
40.0%
2 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus
Clinical Trials (5)
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5